The metabolic syndrome in cancer survivors.
The metabolic syndrome, as a cluster of cardiovascular risk factors, may represent an important connection between cancer treatment and its common late effect of cardiovascular disease. Insight into the aetiology of the metabolic syndrome after cancer treatment might help to identify and treat cancer survivors with increased cardiovascular risk. In this review, we summarise current knowledge on the prevalence and pathophysiology of the metabolic syndrome in cancer survivors, and discuss current intervention strategies with an emphasis on new developments.
Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
Esther C
EC
de Haas
Sjoukje F
SF
Oosting
Joop D
JD
Lefrandt
Bruce Hr
BH
Wolffenbuttel
Dirk Th
DT
Sleijfer
Jourik A
JA
Gietema
D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D015995:Prevalence; D017741:Survivors